首页|期刊导航|中华医学杂志（英文版）|Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy
中华医学杂志（英文版）2024，Vol.137Issue(2)：140-151,12.DOI:10.1097/CM9.0000000000002945
Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy
Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy
摘要
关键词
Measurable/minimal residual disease/Acute lymphoblastic leukemia/Chimeric antigen receptor-modified T-cell therapy/Allogeneic hematopoietic stem cell transplantation/RelapseKey words
Measurable/minimal residual disease/Acute lymphoblastic leukemia/Chimeric antigen receptor-modified T-cell therapy/Allogeneic hematopoietic stem cell transplantation/Relapse引用本文复制引用
Minghao Lin,Xiaosu Zhao,Yingjun Chang,Xiangyu Zhao..Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy[J].中华医学杂志（英文版）,2024,137(2):140-151,12.基金项目
This study was supported by grants from National Nat-ural Science Foundation of China(Nos.81870140 and 82070184),Peking University People's Hospital Research and Development Funds(No.RDL2021-01),Beijing Nova Program(No.20220484235),and Beijing Life Oasis Public Service Center(No.CARTFR-01). （Nos.81870140 and 82070184）
